Continuous glucose monitoring in patients with type 2 diabetes treated with glucagon like peptide 1 receptor agonist dulaglutide in combination with prandial insulin lispro: an AWARD 4 substudy
To conduct a substudy, using 24 hour continuous glucose monitoring (CGM) of the AWARD 4 trial, which was designed to compare insulin glucagon like peptide 1 receptor agonist treatment with an insulin only regimen.
Diabetes, obesity metabolism